Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pipequaline
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Pipequaline is an experimental anxiolytic drug that was never marketed. It is a quinoline derivative with a unique chemical structure distinct from other drugs in its class. Pipequaline acts as a non-selective GABA A receptor partial agonist at the benzodiazepine binding site, providing significant anxiolytic effects with minimal sedative, amnestic, or anticonvulsant activity compared to traditional benzodiazepines. Its pharmacological profile makes it of interest for research into anxiety disorders without the side effects commonly associated with benzodiazepines[1][2][5].
- Other names
- pipequalinapipequalinum2-phenyl-4-(2-(4-piperidyl)ethyl)quinoline
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on pipequaline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pipequaline.